Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120861 · ClinicalTrials.gov registry record · Phase 2
Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00120861: Completed Phase 2 study, sponsored by Merck Sharp & Dohme.
NCT00120861 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00120861, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This study is being conducted to compare the safety, effectiveness and tolerance of valopicitabine (NM283) when used alone and when valopicitabine is used together with pegylated interferon in hepatitis C treatment failure patients. These results will be compared against the results of treatment with pegylated interferon plus ribavirin, the current standard therapy for treatment of hepatitis C viral infection.
Interventions
- DRUG ribavirin
- DRUG valopicitabine
- DRUG pegylated interferon
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-01 |
| Phase | Phase 2 |
What the finished NCT00120861 record still lists
NCT00120861 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which ribavirin is the first listed.
NCT00120861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00120861 about?
NCT00120861 is a clinical study titled "Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy". This study is being conducted to compare the safety, effectiveness and tolerance of valopicitabine (NM283) when used alone and when valopicitabine is used together with pegylated interferon in hepatitis C treatment failure patients. These results will be compared against the results of treatment wit...
What is the current status of trial NCT00120861?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-01.
What interventions are being tested in trial NCT00120861?
The interventions under investigation include: ribavirin (DRUG), valopicitabine (DRUG), pegylated interferon (DRUG).
Who is sponsoring clinical trial NCT00120861?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia